SANTEN PHARMA, Apr-Dec (Cumulative 3Q) Net Income Increases by 3%, Current Fiscal Year Dividend Revised Upward by 2 yen

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Thu Feb 6, 2025 3:00 pm JST Earnings

4536 SANTEN PHARMACEUTICAL CO.,LTD. 【IFRS】

Earnings Report

SANTEN PHARMACEUTICAL CO.,LTD. <4536> [TSE Prime] announced its financial results (based on IFRS) in the afternoon session on February 6th (15:00). The consolidated net income for the cumulative third quarter of the fiscal year ending March 2025 (April to December) increased 3.2% from the same period last year, reaching 27.4 billion yen. The progress rate toward the full-year plan of 32.5 billion yen was 84.5%, it was below the five-year average of 120.6%.

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated net income for the January to March period (4Q) is expected to surge 174 times that of the same period last year, reaching 5.03 billion yen.

At the same time, the company has increased its planned annual dividend for the current fiscal year from the original plan of 34 yen to 36 yen (compared to 33 yen in the previous period).

In the most recent three-month period, from October to December (3Q), the consolidated net income grew 18.5% from the same period last year, reaching 8.69 billion yen. The operating profit margin rose from 14.4% in the same period last year to 14.8%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2022	199,786	-10,147	-11,593	-16,064	-41.1	ー	Feb 7, 2023	IFRS
Apr - Dec, 2023	222,833	36,157	33,559	26,613	72.3	112.3	Feb 8, 2024	IFRS
Apr - Dec, 2024	222,773	35,195	35,309	27,465	78.2	78.5	Feb 6, 2025	IFRS
YoY	0.0%	-2.7%	+5.2%	+3.2%	+8.2%

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024 Prev	155,596	20,627	21,161	13,728	40.2	17	Nov 7, 2024	IFRS
Oct - Mar, 2024 New	155,596	20,627	21,161	13,728	40.2	19	Feb 6, 2025	IFRS
Revision Rate	0.0%	0.0%	0.0%	0.0%	0.0%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	302,000	44,500	45,000	32,500	95.2	34	Nov 7, 2024	IFRS
Mar, 2025 New	302,000	44,500	45,000	32,500	95.2	36	Feb 6, 2025	IFRS
Revision Rate	0.0%	0.0%	0.0%	0.0%	0.0%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	156,159	13,442	5,799	7,362	20.1	17	May 9, 2024	IFRS
Oct - Mar, 2024 Guidance	155,596	20,627	21,161	13,728	40.2	19	Feb 6, 2025	IFRS
YoY	-0.4%	+53.5%	+264.9%	+86.5%	+100.5%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	279,037	-3,090	-5,799	-14,948	-38.6	32	May 11, 2023	IFRS
Mar, 2024	301,965	38,541	29,874	26,642	72.6	33	May 9, 2024	IFRS
Mar, 2025 Guidance	302,000	44,500	45,000	32,500	95.2	36	Feb 6, 2025	IFRS
YoY	+0.0%	+15.5%	+50.6%	+22.0%	+31.2%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	77,027	11,058	9,484	7,333	19.9	14.4	Feb 8, 2024	IFRS
Jan - Mar, 2024	79,132	2,384	-3,685	29	0.1	3.0	May 9, 2024	IFRS
Apr - Jun, 2024	74,771	13,155	13,450	10,633	29.6	17.6	Aug 6, 2024	IFRS
Jul - Sep, 2024	71,633	10,718	10,389	8,139	22.9	15.0	Nov 7, 2024	IFRS
Oct - Dec, 2024	76,369	11,322	11,470	8,693	24.8	14.8	Feb 6, 2025	IFRS
YoY	-0.9%	+2.4%	+20.9%	+18.5%	+24.3%